Merck and Endocyte announce independent DSMB recommends vintafolide PROCEED Phase 3 trial be stopped for futility following interim analysis
2 May 2014 | By Merck
Merck and Endocyte, Inc. announced that the Data Safety Monitoring Board of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped...